Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Cash (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Change in Cash for 4 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 194.38% to $11.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$321.3 million through Dec 2025, down 225.89% year-over-year, with the annual reading at -$321.3 million for FY2025, 225.89% down from the prior year.
  • Change in Cash for Q4 2025 was $11.1 million at Centessa Pharmaceuticals, up from $6.6 million in the prior quarter.
  • The five-year high for Change in Cash was $267.7 million in Q3 2024, with the low at -$278.1 million in Q1 2025.
  • Average Change in Cash over 4 years is -$33.3 million, with a median of -$41.4 million recorded in 2022.
  • The sharpest move saw Change in Cash soared 918.55% in 2024, then plummeted 2733.93% in 2025.
  • Over 4 years, Change in Cash stood at -$51.2 million in 2022, then increased by 15.1% to -$43.5 million in 2023, then surged by 72.84% to -$11.8 million in 2024, then surged by 194.38% to $11.1 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $11.1 million, $6.6 million, and -$60.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.